Descrizione del progetto
Un’innovativa biopsia liquida ad alta sensibilità per la terapia oncologica
L’analisi dei biomarcatori tumorali durante la visita di controllo del trattamento e nel periodo post-operatorio richiede un’elevata sensibilità. Il progetto BiopSense, finanziato dall’UE, sta sviluppando una nuova tecnologia che consente un rilevamento molto sensibile del polimorfismo a singolo nucleotide nei campioni, consentendo lo screening nei punti di assistenza delle biopsie liquide. Questa piattaforma diagnostica rappresenterà un sistema aperto in grado di accogliere la progettazione di nuovi bersagli diagnostici. La tecnologia si basa su un’invenzione brevettata e includerà funzionalità per la preparazione automatizzata dei campioni e la progettazione lab-on-chip. Tra gli obiettivi del progetto figurano la verifica dei componenti completi della piattaforma, nonché la definizione della sensibilità e dell’accuratezza della chimica per la valutazione rispetto a una piattaforma di spettrometria di massa competitiva.
Obiettivo
Extremely high sensitivity is needed for the detection of cancer biomarkers during the follow-up of the treatment or post-operation period. We have identified a novel technology that enables very sensitive detection of single-nucleotide polymorphism from blood, enabling point-of-care screening of liquid biopsies. Our diagnostics platform will consist of new chemistry and device, and is an open system for designing new diagnostic targets. This will enable customized follow-up of the cancer medication in local hospitals and health care centers. The technology is based on our invention (US patent allowed) further developed in the ERC CoG project, but will have features for automated sample preparation and lab-on-chip design, which need to be verified and combined in the complete platform. For pre-commercialization of the technology, the sensitivity and accuracy of the chemistry will be determined and compared against competing mass spectrometric platform (UltraSEEK by Agena), upgrading our technology from phase TRL 4 to TRL 5. Patent shield of the technology is extended and options for transferring IPR from the University are clarified. Results are presented in investor convention and oncology conferences, and negotiations with investors and out-licensors are started. Three international biotech companies take part in the steering group. The technology allows business potential in device and kit production, but especially in international service business for personalised panel components and medical consultation. The expected price of the device and sample prep will be 30-40% cheaper than that of the closest competitor, but even better it allows flexible design of personalized diagnostic panels. The development for boosting the innovation to market will continue either through a spin-out supported by international investors, together with partnering companies, or through out-licensing.
Campo scientifico
Programma(i)
Argomento(i)
Meccanismo di finanziamento
ERC-POC - Proof of Concept GrantIstituzione ospitante
40100 Jyvaskyla
Finlandia